Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edgewise Therapeutics Inc (EWTX) Financials: Revenue, Profit and Cash Flow
Edgewise Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$167.79M, operating cash flow was -$143.82M and free cash flow was -$144.07M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $1.17B.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $191.41M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $123.00K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | -$123.00K |
| Research and development | $151.39M | $126.97M | $90.91M | $54.03M | $32.19M | $14.98M | $8.62M |
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M | -$17.19M | -$9.92M |
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M | -$17.12M | -$9.49M |
| EBITDA | N/A | N/A | N/A | N/A | -$42.94M | -$17.01M | -$9.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.12M | $0 | $0 | $0 | $2.25M |
| Gross profit | $0 | $0 | $0 | N/A | $0 | $0 | $0 | $1.06M | $0 | $0 | $0 | $1.72M |
| Operating income | -$46.14M | -$61.94M | -$54.12M | -$55.98M | -$46.86M | -$42.61M | -$45.96M | -$45.54M | -$40.43M | -$38.11M | -$34.75M | -$33.86M |
| Net income | $1.17B | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -$40.80M | -$39.66M | -$34.13M | -$31.50M | -$28.52M | -$30.14M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.01M by $60.13M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M | $131.14M | $24.54M |
| Current assets | $543.38M | $475.48M | $327.00M | $357.00M | $283.77M | $129.65M | $24.04M |
| Cash and equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M | $104.92M | $23.65M |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M | $4.34M | $41.39M |
| Short-term debt | $1.01M | $996.00K | $980.00K | $608.00K | N/A | N/A | N/A |
| Shareholder equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M | -$33.42M | -$16.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.78B | $479.69M | $518.52M | $552.60M | $583.47M | $613.33M | $454.39M | $486.82M | $511.28M | $531.65M | $553.81M | $340.04M |
| Total liabilities | $147.35M | $31.61M | $25.32M | $30.35M | $24.82M | $24.26M | $24.67M | $27.60M | $22.41M | $21.17M | $18.86M | $21.20M |
| Cash and equivalents | $68.68M | $72.32M | $33.21M | $61.15M | $46.00M | $43.40M | $49.92M | $41.67M | $44.81M | $43.48M | $30.26M | $86.10M |
| Shareholder equity | $1.63B | $448.08M | $493.20M | $522.26M | $558.65M | $589.07M | $429.72M | $459.22M | $488.88M | $510.47M | $534.94M | $318.83M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M | -$14.63M | -$9.17M |
| Capital expenditures | $256.00K | $1.31M | $5.75M | $5.55M | $668.00K | $203.00K | $180.00K |
| Free cash flow | -$144.07M | -$110.34M | -$97.69M | -$58.18M | -$34.17M | -$14.84M | -$9.35M |
| Share repurchases | N/A | N/A | N/A | N/A | $124.00K | $0 | N/A |
| Investing cash flow | -$32.79M | -$184.66M | $102.89M | -$70.58M | -$242.23M | -$24.38M | -$180.00K |
| Financing cash flow | $196.09M | $249.25M | $53.17M | $129.64M | $186.38M | $120.28M | $24.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$78.29M | -$42.47M | -$42.54M | -$38.59M | -$34.78M | -$32.58M | -$37.87M | -$26.96M | -$27.37M | -$26.10M | -$28.60M | -$26.83M |
| Capital expenditures | $17.00K | $32.00K | $260.00K | $73.00K | $89.00K | $50.00K | $44.00K | $70.00K | $1.13M | $28.00K | $144.00K | $161.00K |
| Free cash flow | -$78.31M | -$42.50M | -$42.80M | -$38.66M | -$34.87M | -$32.63M | -$37.91M | -$27.03M | -$28.50M | -$26.13M | -$28.74M | -$26.99M |
Frequently Asked Questions About EWTX
What is Edgewise Therapeutics' annual revenue?
Edgewise Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Edgewise Therapeutics profitable?
No. Edgewise Therapeutics reported net income of -$167.79M for the fiscal year ended Dec 31, 2025.
How much free cash flow does EWTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$143.82M minus capital expenditures of $256.00K produced free cash flow of -$144.07M.
How much debt does Edgewise Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.01M and cash and equivalents of $61.15M.
EWTX pages: Overview, Earnings, Forecast, Financials, Competitors